SAFE vs. Convertible Note vs. Priced Round: How to Choose the Right Instrument for Your Stage

By Holon Law Partners

You’ve built something worth funding. Now comes the question every early-stage founder eventually faces: how do you actually take the money?

The instrument you choose to raise your first or next round of capital isn’t just a paperwork decision. It shapes your cap table, your investor relationships, your future fundraising leverage, and ultimately, how value gets distributed when the company succeeds. Choosing the wrong structure for your stage doesn’t just create legal headaches. It can price you out of your next round, dilute you at the worst possible moment, or leave early investors with expectations that don’t match reality.

Here’s how to think through the three most common early-stage instruments and when each one actually makes sense.

The SAFE: Speed and Simplicity, With Caveats

The Simple Agreement for Future Equity, originally developed by Y Combinator in 2013 and updated to its post-money form in 2018, has become the default instrument for pre-seed and seed rounds, particularly in the tech startup ecosystem. It’s not hard to see why. SAFEs are fast to negotiate, inexpensive to document, carry no interest rate, and have no maturity date. You take the money, the investor gets the right to convert into equity at a future priced round, and everyone moves forward without spending weeks negotiating a term sheet.

But “simple” is a bit of a misnomer once you look at the economics. The two most important terms in any SAFE are the valuation cap, the maximum company valuation at which the investor’s SAFE converts into equity, and the discount rate, which gives the investor a percentage reduction off the price per share at the next round. These terms exist to reward early investors for taking on early risk. They also mean that stacking multiple SAFEs at different caps over time creates a conversion math problem that can surprise founders at Series A if they haven’t modeled it carefully.

The post-money SAFE, now the standard, makes dilution more predictable by calculating ownership on a post-money basis at the time of signing, not at conversion. That’s an improvement. But it also means that every subsequent SAFE you issue dilutes earlier SAFE holders and your own ownership before you’ve raised a single dollar of priced equity.

When it makes sense: You’re pre-revenue or early traction, raising a relatively small amount from angels or seed funds, and speed matters more than negotiating leverage. You want to defer the valuation conversation until you have more data. Your investors are sophisticated enough to understand the instrument and don’t need the structure of a priced round.

The Convertible Note: Debt with an Equity Destination

Before the SAFE existed, the convertible note was the early-stage instrument of choice and it remains widely used, particularly outside of Silicon Valley and in industries where investors are more comfortable with debt instruments than equity derivatives.

Like a SAFE, a convertible note is designed to convert into equity at a future priced round. Unlike a SAFE, it is actual debt. It carries an interest rate, typically 4 to 8 percent, and a maturity date, usually 18 to 24 months out. If the company hasn’t raised a priced round by maturity, the note is technically due. In practice, most convertible notes get extended or renegotiated rather than called, but the maturity date creates a real legal obligation and a leverage point for investors that SAFEs simply don’t have.

Convertible notes also typically include a valuation cap and a discount rate, so the conversion economics are similar to a SAFE. The meaningful differences are the interest accrual, which increases the amount that converts into equity, and the maturity risk, which introduces a deadline that SAFEs deliberately avoid.

For investors who operate in a more traditional lending or private equity mindset, the debt structure of a convertible note can feel more familiar and more protective. Some institutional investors, family offices, and non-tech-sector investors specifically prefer notes over SAFEs for that reason.

When it makes sense: Your investor base is more comfortable with debt instruments. You’re in an industry where SAFE-based fundraising isn’t yet standard. You have a clear near-term path to a priced round within the note’s maturity window. Or your investors want the additional protection, and potential leverage, that a maturity date provides.

The Priced Round: Clarity at a Cost

A priced round, typically a Series Seed or Series A, involves negotiating an actual valuation, issuing preferred stock, and executing a full suite of transaction documents: a term sheet, a stock purchase agreement, investor rights agreements, voting agreements, and right of first refusal provisions. It is the most legally intensive and time-consuming of the three structures, and the most expensive to close.

It is also the clearest. Every investor knows exactly what they own, at what price, and with what rights. There’s no conversion uncertainty, no cap table math to unwind later, and no downstream surprise when the next round prices. For larger raises, generally above $2 to $3 million, though the threshold varies by market, priced rounds are often the right structure simply because the amount of capital being deployed warrants the precision and the investor protections that come with preferred equity.

Priced rounds also come with governance implications. Preferred shareholders typically receive a board seat or observer rights, information rights, pro-rata rights in future rounds, and liquidation preferences that determine how proceeds are distributed at exit. These are meaningful terms, and negotiating them well at the seed stage sets the foundation for every subsequent raise.

When it makes sense: You’re raising a larger amount, typically $2 million or more. You’re bringing in institutional investors who expect the structure and protections of a priced round. You want the clarity of a fixed valuation and defined ownership. Or you’re at a stage where the governance formality of preferred equity is appropriate for the business.

The Decision Framework

No instrument is universally right. The best structure depends on the size of the raise, the sophistication and expectations of your investors, your industry, your timeline to the next round, and how much legal complexity you’re prepared to manage at this stage of the business.

A few practical considerations worth keeping in mind:

First, talk to your investors before you pick the instrument. Some investors have strong preferences. Raising on a SAFE when your lead investor expects a note, or vice versa, wastes everyone’s time.

Second, model your cap table before you sign anything. Whether you’re issuing SAFEs, notes, or preferred stock, understand what your ownership looks like at conversion or closing, and what it looks like after your next raise. Surprises at Series A are avoidable.

Third, don’t treat any of these instruments as truly standard. SAFEs have a standard form. Convertible notes and priced round documents are negotiated. Even SAFE terms, caps, discounts, pro-rata rights, MFN clauses, are negotiable and materially affect your economics.

Final Thoughts

Raising capital is one of the most consequential legal and business decisions a founder makes. The instrument is the architecture of that decision, and like any architecture, getting it right from the start is far less expensive than redesigning it later.

At Holon Law Partners, our transactional attorneys work with founders from the very first raise through exit, helping structure capital transactions that are clean, investor-ready, and built for the long term. If you’re approaching a raise and want to think through which structure fits your situation, we’d be glad to have that conversation.

This article is for informational purposes only and does not constitute legal advice or create an attorney-client relationship. Please consult qualified legal counsel for guidance specific to your situation.